Suppr超能文献

中和抗体7D11与痘病毒L1蛋白结合的结构基础。

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

作者信息

Su Hua-Poo, Golden Joseph W, Gittis Apostolos G, Hooper Jay W, Garboczi David N

机构信息

Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Drive, Rockville, MD 20852, USA.

出版信息

Virology. 2007 Nov 25;368(2):331-41. doi: 10.1016/j.virol.2007.06.042. Epub 2007 Aug 3.

Abstract

Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons. Safety concerns with the currently available smallpox vaccine indicate a need for research on alternative poxvirus vaccine strategies. Molecular vaccines involving the use of proteins and/or genes and recombinant antibodies are among the strategies under current investigation. The poxvirus L1 protein, encoded by the L1R open reading frame, is the target of neutralizing antibodies and has been successfully used as a component of both protein subunit and DNA vaccines. L1-specific monoclonal antibodies (e.g., mouse monoclonal antibody mAb-7D11, mAb-10F5) with potent neutralizing activity bind L1 in a conformation-specific manner. This suggests that proper folding of the L1 protein used in molecular vaccines will affect the production of neutralizing antibodies and protection. Here, we co-crystallized the Fab fragment of mAb-7D11 with the L1 protein. The crystal structure of the complex between Fab-7D11 and L1 reveals the basis for the conformation-specific binding as recognition of a discontinuous epitope containing two loops that are held together by a disulfide bond. The structure of this important conformational epitope of L1 will contribute to the development of molecular poxvirus vaccines and also provides a novel target for anti-poxvirus drugs. In addition, the sequence and structure of Fab-7D11 will contribute to the development of L1-targeted immunotherapeutics.

摘要

由于痘病毒可能被用作生物武器,因此需要采取预防或治疗天花的医学对策。目前可用的天花疫苗存在安全问题,这表明需要研究替代痘病毒疫苗策略。涉及使用蛋白质和/或基因以及重组抗体的分子疫苗是目前正在研究的策略之一。由L1R开放阅读框编码的痘病毒L1蛋白是中和抗体的靶标,已成功用作蛋白质亚基疫苗和DNA疫苗的组成部分。具有强中和活性的L1特异性单克隆抗体(例如,小鼠单克隆抗体mAb-7D11、mAb-10F5)以构象特异性方式结合L1。这表明分子疫苗中使用的L1蛋白的正确折叠将影响中和抗体的产生和保护作用。在此,我们将mAb-7D11的Fab片段与L1蛋白共结晶。Fab-7D11与L1之间复合物晶体结构揭示了构象特异性结合的基础,即识别由二硫键连接在一起的两个环组成的不连续表位。L1这一重要构象表位的结构将有助于分子痘病毒疫苗的开发,也为抗痘病毒药物提供了新靶点。此外,Fab-7D11的序列和结构将有助于开发针对L1的免疫疗法。

相似文献

1
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.
Virology. 2007 Nov 25;368(2):331-41. doi: 10.1016/j.virol.2007.06.042. Epub 2007 Aug 3.
3
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies.
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4240-5. doi: 10.1073/pnas.0501103102. Epub 2005 Mar 10.
4
Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
J Virol. 2016 Apr 14;90(9):4334-4345. doi: 10.1128/JVI.02878-15. Print 2016 May.
5
Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.
J Virol. 2014 Mar;88(5):2677-89. doi: 10.1128/JVI.03200-13. Epub 2013 Dec 18.
6
Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.
PLoS Pathog. 2015 Sep 1;11(9):e1005148. doi: 10.1371/journal.ppat.1005148. eCollection 2015 Sep.
7
Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01621-16. Print 2017 Feb 15.

引用本文的文献

2
Poxvirus structural biology for application to vaccine design.
Trends Immunol. 2025 Jun;46(6):455-470. doi: 10.1016/j.it.2025.04.002. Epub 2025 May 7.
5
Identification of neutralizing nanobodies protecting against poxvirus infection.
Cell Discov. 2025 Mar 25;11(1):31. doi: 10.1038/s41421-025-00771-7.
7
Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus.
Emerg Microbes Infect. 2024 Dec;13(1):2401931. doi: 10.1080/22221751.2024.2401931. Epub 2024 Sep 19.
9
Poxvirus Vaccines: Past, Present, and Future.
Adv Exp Med Biol. 2024;1451:273-287. doi: 10.1007/978-3-031-57165-7_17.
10
Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.
Nat Immunol. 2024 Feb;25(2):307-315. doi: 10.1038/s41590-023-01715-7. Epub 2024 Jan 5.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.
Vaccine. 2007 Feb 26;25(10):1814-23. doi: 10.1016/j.vaccine.2006.11.017. Epub 2006 Nov 27.
3
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Vaccine. 2007 Jan 26;25(7):1214-24. doi: 10.1016/j.vaccine.2006.10.009. Epub 2006 Oct 17.
4
Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.
Virology. 2006 Nov 25;355(2):164-74. doi: 10.1016/j.virol.2006.07.017. Epub 2006 Aug 21.
5
Subunit recombinant vaccine protects against monkeypox.
J Immunol. 2006 Aug 15;177(4):2552-64. doi: 10.4049/jimmunol.177.4.2552.
7
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1882-7. doi: 10.1073/pnas.0510598103. Epub 2006 Jan 25.
9
Poxvirus entry and membrane fusion.
Virology. 2006 Jan 5;344(1):48-54. doi: 10.1016/j.virol.2005.09.037.
10
Poxvirus multiprotein entry-fusion complex.
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18572-7. doi: 10.1073/pnas.0509239102. Epub 2005 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验